Arxis, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of innovative therapies for patients suffering from respiratory diseases. The company's primary focus is on addressing significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Arxis leverages its proprietary technology platform to design and develop novel drug candidates that target specific biological pathways involved in respiratory inflammation and airway remodeling. Its lead product candidate, ARX-101, is an inhaled small molecule being evaluated for its potential to improve lung function and reduce exacerbations in patients with severe respiratory conditions. By utilizing a lung-targeted drug delivery approach, Arxis aims to maximize therapeutic efficacy at the site of disease while minimizing systemic side effects. The company's strategy involves advancing its clinical pipeline through rigorous testing and seeking regulatory approvals to bring life-changing treatments to a global patient population. Arxis is headquartered in the United States and continues to invest in research and development to expand its portfolio of respiratory-focused therapeutics.
Book value of equity per share effectively indicates a firm's net asset value (total assets - total liabilities) on a per-share basis. References: Below 1: the company is trading below its equity. Equal to 1: the company is trading at the exact value of its equity. Above 1: The company is trading above its equity.
Shows how much the market values every dollar of the company's sales.
Shows how much the market values every dollar of the company's EBITDA.
The price-to-cash flow (P/CF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its operating cash flow per share. The ratio uses operating cash flow (OCF), which adds back non-cash expenses such as depreciation and amortization to net income. P/CF is especially useful for valuing stocks that have positive cash flow but are not profitable because of large non-cash charges.
The price-to-free cash flow (P/FCF) ratio is a stock valuation indicator or multiple that measures the value of a stock's price relative to its free cash flow per share. This metric is very similar to the valuation metric of price to cash flow but is considered a more exact measure because it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.
The price-to-earnings ratio is the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS) and is used by investors and analysts to determine the relative value of a company's shares in an apples-to-apples comparison.
Book value per share (BVPS) takes the ratio of a firm's common equity divided by its number of shares outstanding.
Earnings per share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. EPS indicates how much money a company makes for each share of its stock and is a widely used metric for estimating corporate value.
...and much more!